We are currently witnessing a paradigm shift in Deep Sequencing based R&D operations. These technologies are revolutionizing the way we explore new opportunities in the Life Sciences field. Opinion leaders believe that the future impact of these new technologies could be as significant as the impact that PCR technology has had since its discovery in the 1980s.
Immunology is one of the key areas in which NGS / Deep Sequencing could have a major influence. The sequencing of an entire Antibody Repertoire provides an in-depth view regarding the diversity of in-vivo produced and selected antibodies and can generate new insights into the results obtained by traditional phage display techniques.
Analyzing millions of sequences requires specific and performant algorithms, software and IT infrastructure. Taking advantage of more than two decades experience of experience in Molecular Biology, Immunology, Bioinformatics and Immunoinformatics, Software Development, System Architecture, and Intellectual Property, we designed a set of algorithms exclusively dedicated to antibody sequence discovery and integrated into a software suite: Antibody-Extractor©.
Already applied today by a number of companies in Europe and the US, Antibody-Extractor is yielding novel and valuable insights into antibody-based research strategies. Antibody-Extractor makes repetitive, time-consuming and error-prone daily tasks simple and easy to perform. It saves time and maximizes antibody discovery through rationalization of the output generated from deep-sequencing discovery processes.
Antibody-Extractor API framework provides developers with simple and efficient access to Antibody-Extractor algorithms and functions. It’s a is also used as a core package for developing customized Immunoinformatics solutions.
Khalil is the architect and developer of Antibody-Extractor©. He obtained his Ph.D. in Molecular Biology and Biotechnology at the Free University of Brussels in 1994.
Khalil has been working in Molecular Biology, Bioinformatics, Immuno-informatics, and legacy data management for the past 24 years. He has a strong focus on developing Bioinformatics-based solutions for complex multi-disciplinary programs.
As a consultant, he is working for immuno-biotech industry. His primary goal is to provide customers with appropriate customized solutions that enable them to execute their R & D activities more effectively.
He is based in the Ghent area – Belgium.
De Haard, Johannes Joseph Wilhelmus (Breda, NL), Blanchetot, Christophe Frederic Jerome (Breda, NL), Klarenbeek, Alex (IJsselstein, NL), Achour, Ikbel (Chicago, IL, US), El Mazouari, Khalil (Vinderhoute, BE), Del Favero, Jurgen (Tienen, BE) 2015. HIGHLY DIVERSE COMBINATORIAL ANITBODY LIBRARIES. arGEN-X. United States Patent Application 20150166680
Klarenbeek A, El Mazouari K, Desmyter A, Blanchetot C, Hultberg A, de Jonge N, Roovers R C, Cambillau C, Spinelli S, Del-Favero J, Verrips T, de Haard H, Achour I. Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform. MAbs. 2015;7(4):693-706. PMID: 26018625
Roben P1, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994 Aug;68(8):4821-8. PMID: 7518527
Barbas CF 3rd1, Björling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43. PMID: 1384050
Jores R1, Alzari PM, Meo T. Resolution of hypervariable regions in T-cell receptor beta chains by a modified Wu-Kabat index of amino acid diversity. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9138-42. PMID: 2251255